

February 2021

Dear Friends,

Fifty years ago, the families of loved ones with type 1 diabetes (T1D) founded JDRF with a clear and urgent mission: through research, the disease would be cured.

I have never been more excited about the progress we are making. T1D research is advancing at unprecedented rates, with major advances in beta cell therapies and immune therapies that are bringing us closer than ever to cures.

We are prioritizing opportunities and innovating initiatives with the greatest potential to lead us to cures and life-changing advances in the shortest amount of time. This is exemplified by the **JDRF Center of Excellence in Northern California**, where we have gathered some of the most brilliant minds in science, with world-leading institutions to revolutionize beta cell biology and cell replacement solutions without the need for chronic immune-suppression.

This is a monumentally important example of strategy driving life-changing progress and breakthroughs, catalyzed by our shared, unyielding commitment to create a world without T1D.

Many of you know me as the “artificial pancreas guy,” and I am proud of all JDRF has done to accelerate those life-changing systems. But my goal—what I want to be as CEO—is the “cures guy.” I’m pleased to say we are making progress on all fronts. We must continue to push forward and maintain the tremendous momentum that we have regardless of the challenges this year.

Thank you for considering participating in this unique \$3 million campaign to complete the five-year funding commitment of the **JDRF Center of Excellence in Northern California** steering us closer to cures for T1D that all of us so desperately want.

Together, we can seize this moment and lead the fight to end this disease for good. In deepest appreciation, yesterday, today and tomorrow,



Aaron J. Kowalski, Ph.D.
Chief Executive Officer

